reserved.
R cloned from a buffalo rat liver cell line based on its ability to stimulate in vitro proliferation of marrow cells from mice treated with 5-fluorouracil.' rrSCF stimulated increases in cells of multiple hematopoietic lineages in the peripheral blood and corrected the macrocytic anemia of Steel (Sl/Sld) mice.' However, rrSCF failed to enhance the in vitro proliferation of hematopoietic progenitors from W/W mice, which have a defect in expression of the c-kit cell surface receptor? rrSCF is homologous to mast cell growth factor (MGF)3.5 and to growth factor KL both of which appear to be the products of the same genetic locus, SI, in mice. These S1 locus factors (SCF, MGF, and KL) appear to be ligands for c-kit.'" They can exist as both soluble and membrane-bound forms,5" but the precise role of these two forms in the regulation of hematopoiesis is not yet known.
Recombinant human stem cell factor (SCF) was cloned by virtue of its homology with rrSCF.' It has been shown to enhance the proliferation of human colony-forming cells in vitro in the presence of erythropoietin (Epo), granulocyte colony-stimulating factor (G-CSF), granulocyte-macrophage CSF (GM-CSF), or interleukin-3 (IL-3), but stimulated little colony growth by itself. ' The purpose of the present study was to assess the effects of soluble SCF on hematopoiesis both in vitro and in vivo in nonhuman primates. We found that in vitro SCF enhanced the growth of both myeloid and erythroid colony-forming cells, and in vivo it stimulated increases in the number of cells of multiple hematopoietic lineages in the peripheral blood and marrow of baboons, including hematopoietic colony-forming cells.
MATERIALS AND METHODS
Healthy juvenile baboons (Papio cynocephalus or P anubk) were housed at the University of Washington Regional Primate Research Center, under American Association for Accreditation of Laboratory Animal Care (ALLAC)-approved conditions. Studies were conducted under Institutional Review Board and Animal Care and Use Committee approved protocols. Indwelling central venous catheters were inserted via the femoral vein for use with a tether system previously described? Animals were maintained on prophylactic antibiotics to prevent catheter-related infections during the study. Animals were provided with water, biscuits, and fruit ad libitum throughout the study.
All procedures, including bone marrow biopsies and aspirates, were performed after animals had been anesthetized. Marrow
Animals.
of the number of erythrocytes, neutrophils, lymphocytes, monocytes, eosinophils, and basophils. In marrow, it caused an increase in marrow cellularity and in the absolute number of colony-forming unit-granulocyte-monocyte (CFU-GM) and burst-forming unit-erythroid (BFU-E) in marrow following infusion of SCF. The in vivo stimulation of multiple lymphohematopoietic lineages corroborates previous in vitro studies and suggests a potentially important clinical role for SCF. 0 1991 by The American Society of Hematology.
samples were obtained from the iliac crest, distal femur, or proximal humerus. Biopsies were obtained using an 11-gauge Jamshidi biopsy needle and aspirates with a 13-gauge aspiration needle. Aspirates were collected in heparinized 3-mL syringes. Biopsies were fixed in either B-5 or buffered formalin. Blood samples of 1 to 2 mL were obtained in EDTA and in clot tubes two times per week for complete blood cell count (CBC), reticulocyte count (performed in the clinical laboratory of the Primate Center), and chemistries (serum electrolytes, calcium, phosphate, urea nitrogen, creatinine, glucose, total protein, albumin, amylase, alanine aminotransferase [ALT], aspartate aminotransferase [AST], iron, iron-binding capacity, transferrin saturation, ferritin, and zinc protoporphyrin, performed at the University of Washington Hospital Clinical Laboratories). Differential blood cell counts ( 2 100 cells) were determined with each CBC.
SCF was produced in Escherichia coli.* Briefly, E coli cells harboring a runaway expression plasmid' containing the cDNA for human SCF"16, were grown in standard tryptone, yeast extract, and glucose broth. The harvested cells were suspended in water and broken by passage through a Gaulin homogenizer. The broken cell fraction was centrifuged (17,700 x g, 30 minutes). The protein was resolubilized in 8 mol/L urea. The following chromatography steps were used to purify the SCF to homogeneity: acid precipitation at pH 4.5, cation exchange on S-Sepharose fast flow (Pharmacia, Piscataway, NJ), hydrophobic interaction chromatography on C, (Vydac), and anion exchange on Q-Sepharose fast flow (Pharmacia). The final material was resuspended in phosphatebuffered saline. Purified material contained less than 0.033 ng endotoxin per mg SCF protein. Purified material, stored at -7o"C, was thawed and diluted in 50 mL normal saline (Abbot Laboratories, Chicago, IL) containing 0.8% (vol/vol) sterile (0.2 bm filtered) autologous baboon plasma. Material was kept at 4°C during the infusion, as studies showed that SCF was stable in baboon plasma for up to 24 hours at 4°C (data not shown). The doses of both unmodified E coli-derived SCF and PEG-SCF were based on the molecular weight of the unmodified protein, resulting in equal molar quantities per kilogram of body weight being administered to all animals.
Growth factors.
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Baboon marrow cells were isolated by bu@ coat preparation, followed by lysis of residual red blood cells with ammonium chloride buffer." Marrow cells, at 5.0 x 104/mL, were cultured in Iscoves's Modified Dulbecco's Medium (GIBCO, Grand Island, NY) in 0.3% (wt/vol) agar (FMC, Rockland, ME), supplemented with 25% fetal bovine serum (Hyclone, Logan, UT), and 2mercaptoethanol in 35-mm culture dishes (Nunc, Naperville, IL). Recombinant human growth factors IL-6, IL-3, G-CSF, GM-CSF, Epo, and SCF were supplied by Amgen (Thousand Oaks, CA) as purified material and were used in cultures either alone or in combination, each at 100 ng/mL to provide maximal stimulation (based on titers of individual factors).
Cultures were incubated at 37°C in a 5% 0,, 5% CO, humidified incubator. At day 14 of culture, colonies were enumerated using an inverted microscope. Macroscopic BFU-E were defined as those greater than 0.5 mm in diameter.
Monoclonal antibodies to human lymphocyte differentiation antigens that cross-react with baboon lymphocytes were used (data not shown). Antibodies 9.6 (CD2), 51.1 (CD8), and 24.1 (CD10) were used at 1:1,000 dilutions of unfractionated ascites fluids; antibodies G17.2 (CD4) and 1F5 (CD20) were used as purified antibodies at 5 ~g/mL.'~." Antibodies 31A and 1A14 (anti-mouse Thy l.l), as control antibodies of irrelevant specificity, were used as ascites fluids at dilutions of l:l,000.14 Peripheral blood and marrow cells were stained by indirect immunofluorescent antibody binding.Is Cells labeled with IgG antibodies were stained with fluorescein isothiocyanate (FITC)-conjugated goat anti-mouse IgG (y-chain-specific) antisera (Kirkegaard & Perry, Gaithersburg, MD).
Colonylfoming cell assays.
Monoclonal antibodies and immunofluorescent staining.
RESULTS
In vitro stimulation of baboon marrow cells by SCF. We first determined the effects of SCF on the in vitro proliferation of baboon marrow progenitors. SCF alone stimulated the growth of few colonies (Table l) , but when combined with GM-CSF, IL-3, or Epo, SCF increased the number of BFU-E formed and was associated with the appearance of macroscopic (>OS mm diameter) BFU-E and CFU-GM. SCF further increased the total number of BFU-E stimulated by the combination of IL-6, IL-3, G-CSF, GM-CSF, and Epo in culture (mean f SEM, 61 f 6 without SCF; 95 -C 8 with SCF; P < .01). While SCF did not cause a statistically significant increase (P > .2) in the number of 
Data are the mean SEM of three experiments, each performed in triplicate. Each factor was used at 100 ng/mL; SCF was used at 100 ng/mL. *Macroscopic colonies.
tDifferent from control cultures without SCF (P < .05).
CFU-GM, an increase in the size, to greater than 0.5 mm, for a portion of the CFU-GM was also observed. We determined the effect of SCF on in vivo hematopoiesis when administered by continuous intravenous infusion. Two baboons were given unmodified SCF at a dose of 200 kg/kg/d and three animals were given PEG-SCF at a dose equivalent to 200 pglkgld of unmodified SCF protein (see Materials and Methods).
In the two animals receiving unmodified SCF, the total peripheral white blood cell count (WBC) began to increase by 7 to 14 days after starting the infusion, and in the three receiving PEG-SCF, within 4 to 7 days. WBC for all animals reached a peak by 3 weeks, with an overall 3.9 2 0.6 (mean 2 SEM) fold increase (range, 2.9-to 5.3-fold). The total number of neutrophils, lymphocytes, monocytes, eosinophils, and basophils increased during the SCF infusion (Fig 1) . Increases in circulating neutrophils, monocytes, and lymphocytes were most prominent during the first 3 weeks of SCF infusion. Eosinophil and basophil counts increased during the last 2 weeks of the infusions, although they varied between animals. The WBC and absolute number of cells of individual lineages, with the exception of lymphocytes, decreased to levels not statistically different from pretreatment values within 7 days after SCF was discontinued.
The reticulocyte counts increased significantly with the SCF infusions (Fig 2) . The three animals that received PEG-SCF displayed a more rapid increase in reticulocyte counts than did the animals that received unmodified SCF, and they also had detectable nucleated erythrocytes (nRBC) circulating in the peripheral blood from days 7 to 28 of the SCF infusion (range, 2 to 9 nRBCI100 WBC). The maximum reticulocyte count attained was similar for all animals, and the reticulocytosis diminished during the last 2 weeks of SCF infusion. Total red blood cell number, hemoglobin, and hematocrit increased in these animals over the first 3
In vivo stimulation of baboon hematopoiesis by SCF. No significant changes in serum sodium, potassium, chloride. carbon dioxide, calcium, phosphate, urea nitrogen, creatinine, total protein, albumin, amylase. ALT, or AST were found during the course of the SCF infusion. Appetite, behavior, and weight did not change during the study period, nor were fevers detected. One animal developed facial edema, wheezing, and respiratory distress within 2 hours of starting the SCF infusion. The symptoms resolved following administration of epinephrine and discontinuing the infusion. The infusion was restarted the following day without recurrence of symptoms and the animal completed the full 28 days of SCF. One animal given unmodified SCF had low-titer (1:lO) anti-SCF antibodies detected in its serum after completion of the SCF infusion, while the four other animals had no evidence of circulating anti-SCF antibodies."
weeks of the SCF infusion, but were accompanied by a decrease in the mean red blood cell volume (Fig 2) . One animal given PEG-SCF was studied for changes in serum iron, iron-binding capacity, ferritin, and zinc protoporphyrin (Fig3). Associated with the decrease in mean corpuscular volume (MCV), as seen in the other animals given SCF, we observed a decrease in serum iron and transferrin saturation, and an increase in zinc protoporphyrin, suggestive of iron-deficient hematopoiesis. None of the animals received iron supplementation during the studies. Peripheral blood platclct counts in the two animals that received unmodificd SCF initially decreased, but thcn incrcascd to 150% of baselinc valucs by 3 wccks. The platclct count incrcascd to slightly above prctreatmcnt lcvcls aftcr thc cnd of the infusion for two of thc thrcc animals that rcccivcd PEG-SCF (Fig 1) .
Bonc marrow biopsies obtaincd from all treated animals at thc cnd of the SCF infusion showed markcd incrcascs in ccllularity (cstimatcd 160% to 200% of normal, Fig 4) with an incrcasc in mcgakaryocytcs appropriatc for thc ccllularity. Thc approximatc 5:l myeloid to erythroid (M:E) ccll ratios werc unchanged from the M:E ratios before SCF was administcrcd.
Onc baboon given PEG-SCF had marrow biopsies and aspiratcs obtaincd bcforc trcatmcnt and after 7, 14, and 21 days, and a marrow biopsy at 26 days. Aftcr 7 days of PEG-SCF. thc bonc marrow was hypcrccllular (180% of normal) and thc marrow M:E ccll ratio had dccreascd from a prctrcatmcnt valuc of 5.21 to I.3:l. with a predominancc of immaturc mycloid (24.9% myeloblasts and promyclocytcs) and erythroid (31.5% erythroblasts and basophilic normoblasts), and an incrcasc in megakaryocytcs in the marrow. Thc M:E ratio was 2.1:l and 4.1:1 on days 14 and 21, rcspcctivcly, and had rcturncd to thc prctreatmcnt valuc by the end of thc infusion. Thc incidcncc of mycloblasts and promyclocytcs decreased to 7.5% by day 14 and to 3.2% by day 21, and thc incidcncc of immature erythroid cclls rcturncd to prctrcatmcnt lcvcls by day 21. Thc rclative frcqucncy of mcgakaryocytcs in the marrow rcmained incrcascd in proportion to thc overall incrcase in ccllularity, which rcmaincd at 200% of normal throughout thc pcriod of SCF administration. Thcrc was no evidcncc of incrcascd fibrosis in marrow biopsics from any of thc treated animals as dctermincd by rcticulin stains (data not shown).
In vivo stimulation ly SCF of colony-forming cells in marrow of baboons. Marrow CFU-GM and BFU-E werc assaycd from four baboons bcfore and at day 21 (onc animal) and 28 (thrcc animals) of thc SCF infusions. The numbcr of CFU-GM (28.3 % 7.4 prc-SCF, 34.3 2 8.8 post-SCF) and BFU-E (38.4 = 7.1 pre-SCF, 52.7 % 14.4 post-SCF) per 5 x IO' wcrc not statistically different. Howcver, givcn the incrcascs in marrow ccllularity dctcrmincd by bone marrow biopsies (Fig 4) . these data indicate increascs in the absolute numbers of marrow CFU-GM and BFU-E.
Phenorype anarysis of peripheral blood and mamw cells from baboonsgiven SCF. Bccause SCF increased the total numbcr of lymphocytcs in pcriphcral blood, we investigated thc types of lymphocyte subpopulations present in the blood of the two animals givcn unmodified SCF. WC asscsscd thc incidcncc of peripheral blood and marrow cells with low right-angle light-scattering characteristics that cxprcsscd thc CD2, CD4, CD8, CDIO, and CD20 antigens before SCF and at the cnd of the SCF infusion Table 2) . Although the incidence of cells expressing the CD2, CD4, and CD8 antigens was slightly decreased in peripheral blood at the end of the SCF infusion, the absolute number of lymphocytes in the circulation was increased by 2.8-fold. Thus, the total number of these specific lymphocytes in circulation appears to be increased. The ratio of CD4+ to CD8' cells was unchanged to slightly increased. The incidence of CD10' (CALLA+) lymphocytes in the blood and marrow was increased, while the incidence of peripheral blood CD20' cells remained unchanged, suggesting that the total number of these cells was increased.
DISCUSSION
These studies demonstrate that SCF had unique biological effects on hematopoietic cells both in vitro and in vivo in nonhuman primates. In vitro, SCF caused an increase in both the incidence and size of colonies growing in response to specific growth factors including IL-3, GM-CSF, and Epo. This is similar to reported effects of SCF on human marrow progenitors in vitr0.8,'~ In vivo, SCF stimulated increased numbers of erythrocytes, neutrophils, monocytes, and lymphocytes in the peripheral blood. The initial increase in reticulocytes and red blood cell numbers in these animals was followed by a decrease, associated with a decrease in MCV. We hypothesize that these changes may be due, in part, to iron-deficient erythropoiesis, as suggested by the concomitant decrease in serum iron and transferrin saturation, and the increase in zinc erythrocyte protoporphyrin. Of importance, SCF also stimulated an apparent expansion of detectable progenitor cells for both granulocytic/monocytic and erythrocytic lineages in marrow.
The increased numbers of circulating lymphocytes stimulated by SCF may represent the generation of lymphocytes from their progenitors and/or changes in the trafficking of lymphocytes, although the present studies cannot distinguish between these two possibilities. The increases in marrow and peripheral blood CD10' lymphoid cells, representative of presumably immature B cells, would be consistent with the proliferation of B-lymphocyte precursors, and Values are mean f SEM of the percent of cells isolated from blood and marrow of baboons before and after treatment with unmodified SCF with low right-angle light scatter (lymphocyte and blast-sized cells) that labeled with monoclonal antibodies to the CD2, CD4, CD8, CD10, and CD20 antigens. Ratio of CD4:CD8 cells in blood was 1.5 and 1.4 before and after SCF, respectively, while in marrow, the ratio was 0.8 and 1.5 before and after SCF, respectively. *0.1% -c 0.1%.
with the observation that murine pre-B cells are stimulated by SCF in conjunction with IL-7.' Increases in platelet counts were not consistently seen, although an increase in marrow megakaryocytes was observed. By comparison, Sl/Sld mice treated with rrSCF increased their platelet counts by twofold to fourfold. ' The finding that in vitro SCF increased the incidence of proliferating progenitor cells in the presence of other cytokines, while displaying little activity on its own, suggests that the observed in vivo effects may be due to a mechanism involving SCF and other endogenous growth factors. Alternatively, the hematopoietic microenvironment may be more permissive for the proliferation of hematopoietic stem cells, or their immediate progeny, in response to SCF than are in vitro semisolid cultures. The long lag time for increases in peripheral blood cells in response to in vivo SCF administration suggests that the cellular targets of SCF action are more primitive than those of Epo, G-CSF, or GM-CSF, which can elicit much more rapid increases in peripheral blood parameters after in vivo Marked marrow hypercellularity and an increase in the number of CFU-GM and BFU-E was observed after as few as 7 days of treatment with SCF and was maintained throughout the period of SCF administration. We also observed significant increases in the numbers of CFC in the peripheral blood (Andrews et al, unpublished observations). This is in contrast to results obtained treating humans with G-CSF, or GM-CSF after chemotherapy, where an increase in the number of CFC was observed in the peripheral blood, but not in marrow, where an apparent decrease in their number was f o~n d ?~, '~ The findings in the present study are consistent with a systemic expansion of CFU-GM and BFU-E in marrow and in peripheral blood, although additional effects on trafficking of these progenitor cells may also play a role. Whether the expansion of CFC is due to generation from a more primitive population of stem cells that require SCF plus other growth factors for growth or from apparent self-renewal of more mature CFC cannot be determined from these studies. In vitro studies demonstrate that SCF in combination with other growth factors dramatically stimulates colony formation by and generation of colony-forming cells from CD34'lin-precursor cells in human marrow."
Thus, SCF is a potent cytokine that can stimulate increases in the number of progenitor cells and mature cells of both myeloid and lymphoid lineages in peripheral blood and marrow. These results suggest that SCF may have an important role in clinical therapies.
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